Hyaluronidase

Hyaluronidase is enzyme that catalyzes the breakdown of hyaluronic acid. Hyaluronidase is found in the mammalian testicular and spleen tissues, in bees and snake venoms and in certain species of Clostridium, Staphylococcus and Streptococcus. Hyaluronidase is used clinically to facilitate the administration of fluid by hypodermoclysis. Hyaluronidase is used to render the tissues more readily pormeable to injected fluids e.g for introduction of fluids by sub-cutaneously infusion.

Brands
VISCOAT
Adult Dose
Dose: 1500 IU
Single Dose: 1500 (1500)
Frequency: As recommended.
Route: IM,SC
Instructions: Per Infusion or As Required
Neonatal
Dose: 1500 IU
Single Dose: 1500 (1500)
Frequency: As recommended.
Route: Intra Muscular
Instructions: Total Dose
Paedriatic
Dose: 1500 IU
Single Dose: 1500 (1500)
Frequency: As recommended.
Route: Intra Muscular
Instructions: Total Dose
Characteristics
. It is of Natural origin and belongs to CHO. It belongs to Hyaluronidase Enzyme pharmacological group on the basis of mechanism of action and also classified in Antidotes and Enzyme pharmacological group.The Molecular Weight of Hyaluronidase is 6100000000.00. Its pKa is 8.6 0000000.
Contraindications
Hyaluronidase is contraindicated in conditions like Infections.
Effects
Hyaluronidase produces potentially life-threatening effects which include Hypersensitivity reactions, Anaphylactic shock. which are responsible for the discontinuation of Hyaluronidase therapy.The symptomatic adverse reactions produced by Hyaluronidase are more or less tolerable and if they become severe, they can be treated symptomatically, these include Edema, Bruising, Local irritation, Bleeding, Bruising.
Indications
Hyaluronidase is primarily indicated in conditions like Bleeding from oesophageal varices, Enhance permeation of SC or IM inj, Extravasation/haematoma, Local anaesthesia, Permeation of injections, Primary nocturnal enuresis, Prophylaxis of vascular headache, Treatment of osteoporosis in post menopausal women, and can also be given in adjunctive therapy as an alternative drug of choice in Arachnoiditis, Myocardial infarction, Peripheral circulatory disorders.
Interactions
No data regarding the interactions of Hyaluronidase was found.
Interfrence
None well documented
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Inj
Warnings
Hyaluronidase should not be administered by intravenous injection. It should not be applied directly to cornea. It should not be used to reduce the swelling of bites or stings.It should be cauutiously given to infants and elderly not for intra venous administration.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.